Biocryst Pharmaceuticals INC (BCRX) — 10-Q Filings

All 10-Q filings from Biocryst Pharmaceuticals INC. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

BioCryst Swings to Profit on Robust Revenue Growth — Nov 4, 2025 Risk: medium
BioCryst Pharmaceuticals Inc. reported a significant turnaround in its financial performance for the nine months ended September 30, 2025, achieving a net incom
BioCryst Narrows Q2 Loss by 47% on Strong ORLADEYO Sales — Aug 5, 2025 Risk: medium
BioCryst Pharmaceuticals Inc. reported a significant increase in revenue for the three and six months ended June 30, 2025, primarily driven by sales of ORLADEYO
BioCryst Pharmaceuticals Files Q1 2025 10-Q — May 6, 2025 Risk: medium
BioCryst Pharmaceuticals Inc. filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial position and operational updates.
BioCryst Pharmaceuticals Files Q3 2024 10-Q — Nov 5, 2024 Risk: medium
BioCryst Pharmaceuticals Inc. reported its third-quarter 2024 results, ending September 30, 2024. The company's financial statements and operational details are
BioCryst Pharmaceuticals Files 10-Q for Q2 2024 — Aug 6, 2024 Risk: medium
BioCryst Pharmaceuticals Inc. reported its financial results for the period ending June 30, 2024. The company's filing details its financial position and perfor
BioCryst Pharmaceuticals Inc. Files 10-Q for Period Ending March 31, 2024 — May 7, 2024 Risk: low
BIOCRYST PHARMACEUTICALS INC (BCRX) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. BioCryst Pharmaceuticals Inc. filed a 10-Q report for the perio

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX